Contents
Academic literature on the topic 'Wang luo ying xiao'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Wang luo ying xiao.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Wang luo ying xiao"
1
Zhang, Xiao-ge, and Jin Wang. "Ying-luo Wang: A Brief Biography." Frontiers of Engineering Management 1, no. 3 (2014): 324. http://dx.doi.org/10.15302/j-fem-2014045.
Full text
2
Gao, Yunfei, Tomoki Uchiyama, Kentaro Yamamoto, Toshiyuki Matsunaga, Toshiharu Teranishi, Ryota Sato, Hideto Imai, Yoshiharu Sakurai, Yoichiro Tsuji, and Yoshiharu Uchimoto. "Exploring the Function of Nitrogen-Doped Carbon Shell on Ordered and Disordered PtCo Alloy Catalysts in Oxygen Reduction Reaction By X-Ray Absorption Spectroscopy." ECS Meeting Abstracts MA2022-02, no. 42 (October 9, 2022): 1549. http://dx.doi.org/10.1149/ma2022-02421549mtgabs.
Full textAbstract:
The development of proton exchange membrane fuel cells (PEMFCs) has received increasing attention for its potential to get rid of dependence on fossil fuels and curb carbon emissions[1]. However, the application of PEMFC has been limited by the consumption of platinum due to the sluggish kinetics of the cathode reaction and limiting platinum reserves. So far, forming Pt-M (M = non-precious metal) alloying phase catalysts has been regarded as an efficient method to improve the activity and decrease the cost of platinum. However, the introduction of the non-precious metal content will decrease the stability of the catalysts by accelerating the dissolution of metal atoms and agglomeration of the nanoparticles[2]. In this research, the nitrogen-doped carbon coating structure was applied to protect the PtCo nanoparticles. And both ordered (I-PtCo@CNx) and disordered (D-PtCo@CNx) PtCo alloy phase core was synthesized to further explore the role of nitrogen-doped carbon shell in improving the activity and stability. To study the electronic statement and structure changes of the catalysts, both in-situ and ex-situ X-ray absorption spectroscopy (XAS) was applied at BL36XU at SPring-8. The synthesis of order PtCo catalysts, generally, requires a high temperature to overcome the energy barrier of forming the ordering phase, which will cause severe Ostwald ripening and get larger nanoparticles[3]. However, in the participation of nitrogen-doped carbon shells, the particle size could be limited to less than 5 nm. The I-PtCo@CNx exhibited high mass activity and specific activity at 1.08 A mgPt -1 and 1.51 mA cmPt -2, respectively. The XAS and X-ray photoelectron spectroscopy (XPS) analysis showed the decreased electronic density on the I-PtCo@CNx compared with I-PtCo catalysts, which suggested the increase of the activity might be originated from the interaction from the nitrogen-doped carbon shell. Furthermore, the accelerate durability tests (ADTs) were applied to measure the stability of the catalysts. In the rotating disk electrode and fuel cell condition, after 30,000 cycles ADTs, the activity of I-PtCo@CNx showed less decrease compared with other samples. The EXAFS analysis confirmed the high stability of I-PtCo@CNx might come from the less oxygen species generation during the ADTs, especially for the Co, and the confined structure benefits to maintaining the structure. In addition, the operando XAS analysis of the membrane electrode assemblies (MEA) samples also showed the high stability of I-PtCo@CNx after polarization at 1.1 V for 1 h. Figure 1. The Pt L3 edge and Co K edge FT-EXAFS spectra of disordered-PtCo, ordered-PtCo, and ordered-PtCo@CNx in different ADTs cycles at 80 °C in MEA operation condition. Acknowledgement This work was supported by the project (JPNP20003) and a NEDO FC-Platform project commissioned by the New Energy and Industrial Technology Development Organization (NEDO). And China Scholarship Council (CSC) was acknowledged for the doctoral scholarship of Yunfei Gao (202006270046). Reference s : [1] Zhao L.; Zhu J.; Zheng Y.; Xiao M.; Gao R.; Zhang Z.; et al. Adv. Energy Mater. 2022, 12, 2102665. [2] Sun Y.; Polani S.; Luo F.; Ott S.; Strasser P.; Dionigi F. Nat. Commun. 2021, 12 (1), 5984. [3] Yang C.; Wang L.; Yin P.; Liu J.; Chen M.; Yan Q.; et al. Science 2021, 374 (6566), 459-64. Figure 1
3
FU, YANZHE, and DIYING HUANG. "New data on fossil mimarachnids (Hemiptera, Fulgoromorpha, Fulgoroidea) in mid-Cretaceous Burmese amber." Palaeoentomology 3, no. 3 (June 30, 2020): 317–31. http://dx.doi.org/10.11646/palaeoentomology.3.3.12.
Full textAbstract:
Mimarachnidae is an extinct planthopper family of the superfamily Fulgoroidea, with ten genera from the Cretaceous of Eurasia. Here, we describe a new genus, Cretodorus gen. nov. and two new species, Cretodorus granulatus sp. nov. and C. angustus sp. nov., on the basis of four specimens from the mid-Cretaceous amber of northern Myanmar. This remarkable genus can be separated from all other mimarachnids as follows: moderately elongate head, anteriorly protruded pronotum with straight lateral carinae, and unbranched MP of tegmen. Additionally, a new species of Burmissus Shcherbakov, 2017, Burmissus latimaculatus sp. nov., is described from the same Burmese amber, and the morphological characters of Burmissus szwedoi Luo, Jiang, Wang & Xiao, 2020 are supplemented for pronotum, clypeus, rostrum, and legs. These new discoveries enrich the palaeodiversity of mimarachnid planthoppers to fifteen species, ten of which are described from the mid-Cretaceous Burmese amber, suggesting that this extinct family remained highly diverse during this period.
4
LI, GUOLIANG, WENLIANG MA, AIMEI GAO, HONGYU CHEN, DAVID FINLOW, and QIAN-SHU LI. "DENSITY FUNCTIONAL THEORY STUDIES OF CHARGED, COPPER-DOPED, SMALL SILICON CLUSTERS, ${\rm CuSi}_{n}^{+}/{\rm CuSi}_{n}^{-}$ (n = 1–7)." Journal of Theoretical and Computational Chemistry 11, no. 01 (February 2012): 185–96. http://dx.doi.org/10.1142/s0219633612500125.
Full textAbstract:
The structures and stabilities of charged, copper-doped, small silicon clusters [Formula: see text] (n = 1–7) have been systematically investigated using the density functional theory method at the B3LYP/6-311+G* level. For comparison, the geometries of neutral CuSi n clusters were also optimized at the same level, although most of them have been reported previously [see Xiao CY, Abraham A, Quinn R, Hagelberg F, Comparative study on the interaction of scandium and copper atoms with small silicon clusters, J Phys Chem A106:11380, 2002; Liu X, Zhao GF, Guo LJ, Wang XW, Zhang J, Jing Q, Luo YH, First-principle studies of the geometries and electronic properties of Cu m Si n (2 ≤ m + n ≤ 7) clusters, Chin Phys16:3359, 2007]. Our results for the ground state structures of neutral CuSi n clusters agree well with those of Liu et al. and Xiao et al. except for CuSi3 and CuSi7 . Removing or adding an electron greatly changes some ground state structures, i.e. for [Formula: see text], [Formula: see text], [Formula: see text], [Formula: see text], and [Formula: see text]; others are almost unchanged, e.g. [Formula: see text], [Formula: see text], [Formula: see text], [Formula: see text], [Formula: see text]. The ground states of ionic [Formula: see text] are all singlet, except for the smaller CuSi- and [Formula: see text]. Based on the optimized geometries, various energetic properties, including binding energies, second-order difference energies, the highest occupied molecular orbit and the lowest unoccupied molecular orbital (HOMO–LUMO) energy gaps, ionization potential and electron affinities, were calculated for the most stable isomers of [Formula: see text]. All the results indicate that anionic [Formula: see text] and cationic [Formula: see text] clusters are relatively stable. The higher stability of the latter has been confirmed by Beck's observations.
5
Qiu, Cuipeng, Xiao Wang, Bofei Wang, Yangcheng Ma, Xiaojun Zhang, and Jian-Ying Zhang. "Abstract 5149: Autoantibodies to PAX5, PTCH1 and GNA11 as serological biomarkers in the detection of hepatocellular carcinoma in Hispanic Americans." Cancer Research 82, no. 12_Supplement (June 15, 2022): 5149. http://dx.doi.org/10.1158/1538-7445.am2022-5149.
Full textAbstract:
Abstract Liver cancer, especially hepatocellular carcinoma (HCC), is the third cause of cancer death worldwide. In the United States, it remains higher incidence rates and worse survival in the Hispanic population than the other populations. Studies have demonstrated that autoantibodies to tumor-associated antigens (TAAs) could be biomarkers with low-cost, efficient, and highly sensitive characteristics. In this study, enzyme-linked immunosorbent assay (ELISA) was conducted to measure three autoantibodies to PAX5, PTCH1, and GNA11 in sera from 25 Hispanic Americans with HCC, 28 patients with liver cirrhosis (LC), and 27 patients with chronic hepatitis (CH) as well as sera from 85 healthy individuals. At the 95% specificity for healthy controls, 56%, 48%, and 44% of HCC sera (or patients) showed elevated levels of autoantibodies to PAX5, PTCH1, and GNA11 respectively. Among the patients with LC, frequencies for autoantibodies to PAX5, PTCH1, and GNA11 were 44%, 36%, and 25% respectively. In patients with CH, the frequencies of autoantibodies to PAX5, PTCH1, and GNA11 were 22%, 22%, and 15%, which were significantly lower than those in HCC (p<0.01). The area under the curves (AUCs) of autoantibodies to PAX5, PTCH1, and GNA11 for identifying HCC from healthy controls were 0.912, 0.915, and 0.915, respectively. The sensitivity could be improved to 68% when three of the autoantibodies were combined with the AUC of 0.932. Therefore, autoantibodies to PAX5, PTCH1, and GNA11 showed significantly higher levels in Hispanic HCC than those in the CH or healthy controls. Also, these three autoantibodies could enhance the detection of HCC if they were combined as the parallel test. In conclusion, autoantibodies to PAX5, PTCH1, and GNA11 could be potential biomarkers for the detection of HCC in Hispanic Americans. Large size of samples is needed to further determine their potential value in clinical application. Citation Format: Cuipeng Qiu, Xiao Wang, Bofei Wang, Yangcheng Ma, Xiaojun Zhang, Jian-Ying Zhang. Autoantibodies to PAX5, PTCH1 and GNA11 as serological biomarkers in the detection of hepatocellular carcinoma in Hispanic Americans [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5149.
6
Li, Yiqun, Hongnan Mo, Xiuwen Guan, Shaoyan Lin, Zijing Wang, Yimeng Chen, Shanshan Chen, et al. "Abstract P1-16-06: In real world, a high percentage of premenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer receive chemotherapy as first-line treatment: A study of the National Cancer Center, China." Cancer Research 82, no. 4_Supplement (February 15, 2022): P1–16–06—P1–16–06. http://dx.doi.org/10.1158/1538-7445.sabcs21-p1-16-06.
Full textAbstract:
Abstract Background: In this study, we aimed to observe initial palliative treatment choices and clinical outcomes for premenopausal hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer patients (MBC) in the Chinese population in real life.Methods: The China National Cancer Center database was used to identify 2194 MBC patients diagnosed between 2004 to 2015. Premenopausal patients with HR+ HER2- MBC were included. Clinicopathological features, initial palliative treatment choices and survival information were extracted. First-line progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan–Meier method and compared using the log-rank test. Prognostic factors associated with OS were analyzed using Cox regression model with 95% confidence interval (95%C.I.).Results: A total of 451 premenopausal patients meeting study criteria were identified. Median age was 44 years. The number of patients receiving chemotherapy alone, endocrine therapy and chemotherapy followed by endocrine therapy as initial palliative treatment strategy were 222(49.2%), 80 (17.7%), and 149 (33.0%), respectively. Patients receiving initial chemotherapy were more likely to be luminal B subtype, had more de novo stage IV disease than recurrent disease and had more liver metastasis, compared with patients receiving initial endocrine therapy. Both PFS and OS were significantly longer for chemotherapy-endocrine therapy group (median PFS 18.9 months and OS 75.0 months), than for endocrine therapy group (median PFS 11.7 months and OS 53.5 months). Chemotherapy alone group presented with worst survival outcomes (median PFS 7.1 months and OS 43.9 months). However, in multivariate analysis, none of the three treatment strategies were independently associated with PFS or OS.Conclusions: In real world, a high percentage of premenopausal patients with HR+ HER2- disease received chemotherapy as initial palliative treatment in China, which was not associated with worsened survival. This unexpected guideline non-adherence reflects the unmet need of establishing treatment guidelines specifically for premenopausal patients in the Chinese population. Further studies with larger sample size across China are needed to explore the relationship between this guideline non-adherence and clinical outcomes. Citation Format: Yiqun Li, Hongnan Mo, Xiuwen Guan, Shaoyan Lin, Zijing Wang, Yimeng Chen, Shanshan Chen, Qiao Li, Ruigang Cai, Jiayu Wang, Yang Luo, Ying Fan, Peng Yuan, Pin Zhang, Qing Li, Fei Ma, Binghe Xu. In real world, a high percentage of premenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer receive chemotherapy as first-line treatment: A study of the National Cancer Center, China [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P1-16-06.
7
Qin, Xiaoli, Lori Luo, Li Ying-ying, Yin Wang, Shuaijun Sun, Xiaolin Hao, and Jinfu Yang. "Abstract CT526: A Phase 1/2a Study of a PI3Kδγ dual inhibitor ZX-101A in patients with advanced solid tumors." Cancer Research 82, no. 12_Supplement (June 15, 2022): CT526. http://dx.doi.org/10.1158/1538-7445.am2022-ct526.
Full textAbstract:
Abstract ZX-101A is a next-generation PI3Kδ/γ dual inhibitor, exerting synergistic effects on PI3Kδ and PI3Kγ-mediated processes through multifaceted mechanisms of actions. Phase 1/2a study, ZX-101A-101 (NCT04504708) is ongoing to assess safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy in patients with advanced hematologic malignancies. Furthermore, recent preclinical studies of ZX-101A showed that dual inhibition of PI3Kδ and PI3Kγ restored the immune surveillance to inhibit solid tumor growth. ZX-101A-201 is a phase 1/2a open-label, multiple-dose ascending study to investigate the safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of once daily oral ZX-101A in 28-day cycles in patients with advanced solid tumors.ZX-101A had minimal effects on solid tumor-derived CT26, 4T1 and A20 cells in in vitro cell proliferation assay. In contrast, ZX-101A inhibited tumor growth when CT26 cells were grafted to wild-type syngeneic mice, while only showed a limited tumor growth inhibition when CT26 tumors grew on T-cell deficient nude mice. Thus, in vivo tumor growth inhibition in wild-type mice was attributed to the enhanced anti-tumor immunity by ZX-101A treatment. Flow cytometry analysis on ex vivo tumor tissues from syngeneic mouse demonstrated that ZX-101A decreased regulatory T cells and increased M1/M2 macrophage polarization in the tumor microenvironment. In A20 syngeneic model, ZX-101A in combination of anti-PD1 antibody achieved 99.7% TGI after 18 days of treatment, while anti-PD1 antibody alone only had TGI at 11.7%. Synergistic inhibitory effect of ZX-101A and anti-PD1 antibody was also observed in LLC, CT26 and humanized MC38 syngeneic mouse models. Safety assessment on the mouse spleen, thymus and colon organs indicated minimal side effects by the treatment of the ZX-101A alone and in combination with anti-PD1. These results suggested ZX-101A as a potential immunotherapeutic agent to treat appropriate solid tumor types. ZX-101A-201 study consists of 2 parts, Dose Escalation and Dose Expansion. Part 1 dose escalation is designed to determine the safety, tolerability, and recommended phase 2 dose (RP2D) of ZX-101A monotherapy in patient with advanced solid tumors. Part 2 dose expansion will evaluate ZX-101A activity in up to three disease-specific cohorts. Inclusion of combination therapy is planned after obtaining the initial clinical assessment of ZX-101A on its safety, tolerability, pharmacokinetics, and pharmacodynamics in patients. Citation Format: Xiaoli Qin, Lori Luo, Li Ying-ying, Yin Wang, Shuaijun Sun, Xiaolin Hao, Jinfu Yang. A Phase 1/2a Study of a PI3Kδγ dual inhibitor ZX-101A in patients with advanced solid tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr CT526.
8
Pahlevaninezhad, Maedeh, Damilola Momodu, Majid Pahlevani, and Edward P. L. Roberts. "Carbon Paper Electrodes Modified with Bismuth for Enhancing the Performance of Vanadium Redox Flow Batteries." ECS Meeting Abstracts MA2022-01, no. 3 (July 7, 2022): 493. http://dx.doi.org/10.1149/ma2022-013493mtgabs.
Full textAbstract:
Redox flow batteries (RFBs) are a promising technology for grid scale stationary energy storage to complement renewable energy systems. Although RFBs have a relatively low energy density, they offer important benefits such as long lifetime, decoupled energy and power, high round-trip efficiency, scalability and design flexibility, fast response and low environmental impacts. These benefits make them superior to many other stationary energy storage technologies [1-3]. The vanadium RFB (VRFB) is the most widely used RFB in industry for grid scale energy storage and for integration of renewable energy generation systems [4]. However, due to their slow redox reaction rates, their performance and stability are limited and VRFBs would thus benefit from enhancement of the electrode kinetics [5]. Various catalysts have been employed to improve the redox reaction rates [5-6]. Bismuth is considered a suitable candidate due to its good reactivity with oxygen, low toxicity, relatively low cost and comparable catalytic properties to other metal competitors [5, 7-8]. In this study, we present a novel modified VRFB electrode composed of carbonized bismuth-polyaniline (Bi-PANI) on a thermally-treated carbon paper substrate. The battery performance was evaluated in a 5 cm2 flow cell using a ‘zero-gap’ design with a 1.6 M VOSO4 in 3 M H2SO4 electrolyte. Charge-discharge of the VRFB was performed at a constant current density (ranging from 10 to 80 mA cm−2) with upper and lower voltage cut-offs of 1.65 and 0.8 V, respectively. Thermally treated carbon paper electrodes were tested as a comparison, and it was found that the VRFB efficiency was significantly enhanced, from 51% to 68% at a current density of 80 mA cm− 2, due to the modification of the electrodes with Bi-PANI. The charge-discharge capacity was also improved by around 17.2%. In addition, the stability of the battery using the modified electrodes was evaluated for over 200 cycles. The improved battery performance was attributed to the catalytic effect of the Bi particles on the VO2+/VO2 + and V2+/V3+ redox reactions leading to a significant increase in capacity, voltage, and energy efficiency. References: [1] M. Skyllas-Kazacos, L. Cao, M. Kazacos, N. Kausar, A. Mousa, ChemSusChem. 9 (2016) 1521–1543. [2] A.K. Singh, M. Pahlevaninezhad, N. Yasri, E. Roberts, ChemSusChem. (2021). [3] M. Pahlevaninezhad, P. Leung, M. Pahlevani, F. C. Walsh, C. Ponce de Leon, and E. P. L. Roberts, Experimental and Computational Studies of Disperse Blue-1 in Organic Non-Aqueous Redox Flow Batteries, J. Power Sources, Volume 500, 15 July 2021, 229942. [4] X.Z. Yuan, C. Song, A. Platt, N. Zhao, H. Wang, H. Li, K. Fatih, D. Jang, Int. J. Energy Res. (2019). [5] S. Moon, B.W. Kwon, Y. Chung, Y. Kwon, Journal of The Electrochemical Society, 166 (12) A2602-A2609 (2019) [6] W. Lee, C. Jo, S. Youk, H. Y. Shin, J. Lee, Y. Chung, and Y. Kwon, Appl. Surf. Sci., 429, 187 (2018) [7] Z González, A. Sánchez, C. Blanco, M. Granda, R. Menéndez, and R. Santamaria, Electrochem. Commun., 13, 1379 (2011). [8] B. Li, M. Gu, Z. Nie, Y. Shao, Q. Luo, X. wei, X. Li, J. Xiao, C. Wang, V. Sprenkle, and W. Wang, Nano Lett., 13, 1330 (2013).
9
Zuo, Wenhua, Guiliang Xu, and Khalil Amine. "The Air Stability of Sodium Layered Oxide Cathodes." ECS Meeting Abstracts MA2022-02, no. 7 (October 9, 2022): 2594. http://dx.doi.org/10.1149/ma2022-0272594mtgabs.
Full textAbstract:
Sodium-ion batteries (NIBs) are listed as one of the ideal alternatives for lithium-ion batteries (LIBs), due to the abundant sodium resources, cost-effective electrode materials of NIBs, and same architecture of NIBs to LIBs. To enable the practical implementation of NIBs, advanced cathodes with higher energy/power densities, better safety and cycle life, as well as lower cost are required. Layered lithium transition metal oxides (LiTMO2) are one of the most successful cathode materials for commercial LIBs. Similarly, layered sodium transition metal oxides (NaxTMO2, also termed as sodium layered oxides) are of particular interest for commercial NIBs owing to their high specific capacity, a wide variety of redox-active elements, and the possibility for the manufacturers to employ established synthesis processes as their lithium counterparts. Sodium layered oxides are built up by ordered stacking of alternate alkali-metal (Na+) layers and transition metal layers (TmO2). The two-dimensional structure makes them the natural hosts for alkali-metal ions and other ions or small molecules, such as H2O. Therefore, when exposed to moist atmospheres, layered oxide materials tend to react with H2O which adsorbed on their surface and thus deteriorate their structure and electrochemical performances. Accordingly, the air-sensitive sodium layered oxides should be well protected from the moist atmospheres, rendering a higher manufacturing and preservation cost. Here, based on the reaction mechanisms, critical influencing factors, and modification methods of layered oxides in moisture, we try to reach a comprehensive understanding of the air-stability of sodium layered oxides. Moreover, future efforts to resolve the air-stability of sodium layered oxides from Argonne National Laboratory will be also presented. References 1. Han, M. H.; Gonzalo, E.; Singh, G.; Rojo, T. A comprehensive review of sodium layered oxides: powerful cathodes for Na-ion batteries. Energy Environ. Sci. 2015, 8, 81-102. 2. Zuo, W.; Qiu, J.; Liu, X.; Ren, F.; Liu, H.; He, H.; Luo, C.; Li, J.; Ortiz, G. F.; Duan, H.; Liu, J.; Wang, M. S.; Li, Y.; Fu, R.; Yang, Y. The stability of P2-layered sodium transition metal oxides in ambient atmospheres. Commun. 2020, 11, 3544. 3. Xu, G. L.; Liu, X.; Zhou, X.; Zhao, C.; Hwang, I.; Daali, A.; Yang, Z.; Ren, Y.; Sun, C. J.; Chen, Z.; Liu, Y.; Amine, K. Native lattice strain induced structural earthquake in sodium layered oxide cathodes. Commun. 2022, 13, 436. 4. Zuo, W.; Xiao, Z.; Zarrabeitia, M.; Xue, X.; Yang, Y.; Passerini, S. Guidelines for Air-Stable Lithium/Sodium Layered Oxide Cathodes. ACS Materials Letters 2022, 4, 1074-1086. 5. Fu, F.; Liu, X.; Fu, X.; Chen, H.; Huang, L.; Fan, J.; Le, J.; Wang, Q.; Yang, W.; Ren, Y.; Amine, K.; Sun, S. G.; Xu, G. L. Entropy and crystal-facet modulation of P2-type layered cathodes for long-lasting sodium-based batteries. Commun. 2022, 13, 2826.
10
Cheng, Ying, Jie Wang, Caicun Zhou, Wenxiu Yao, Qiming Wang, Xuhong Min, Gongyan Chen, et al. "Abstract CT038: Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage SCLC: A phase 3 trial." Cancer Research 82, no. 12_Supplement (June 15, 2022): CT038. http://dx.doi.org/10.1158/1538-7445.am2022-ct038.
Full textAbstract:
Abstract Introduction: Extensive-stage small cell lung cancer (ES-SCLC) is associated with limited treatment options and poor prognosis. Immunotherapy has recently showed robust clinical activity in ES-SCLC. In this double-blind, phase 3 trial, we evaluated adebrelimab (SHR-1316), a novel anti-PD-L1 antibody, in combination with standard chemotherapy (chemo) as first-line treatment for ES-SCLC. Methods: Patients naïve to systemic treatment for ES-SCLC were randomized 1:1 to receive 4-6 cycles of adebrelimab (20 mg/kg, iv, d1, q3w) or placebo with carboplatin (AUC 5, d1, q3w) plus etoposide (100 mg/m2, d1, d2, d3, q3w), followed by maintenance therapy with adebrelimab or placebo. The primary endpoint was overall survival (OS). Results: 462 patients were randomized and treated (adebrelimab+chemo, n=230; placebo+chemo, n=232). As of Oct 08, 2021, with an median follow-up of 13.5 mo (all patients; 22.5 mo for patients alive), OS was significantly prolonged with adebrelimab+chemo vs placebo+chemo (median, 15.3 mo [95% CI 13.2-17.5] vs 12.8 mo [95% CI 11.3-13.7]; hazard ratio [HR], 0.72 [95% CI 0.58-0.90], 1-sided p=0.0017); OS rate was 62.9% vs 52.0% at 12 mo and 31.3% vs 17.2% at 24 mo. Progression-free survival (PFS) per independent review committee (IRC) was 5.8 mo (95% CI 5.6-6.9) with adebrelimab+chemo vs 5.6 mo (95% CI 5.5-5.7) with placebo+chemo (HR 0.67, 95% CI 0.54-0.83); PFS rate was 49.4% vs 37.3% at 6 mo and 19.7% vs 5.9% at 12 mo. Objective response rate (ORR) and duration of response (DoR) also favored the adebrelimab+chemo group (Table 1). Grade ≥3 treatment-related adverse events occurred in 85.7% vs 84.9% of patients with adebrelimab+chemo vs placebo+chemo, with the most common (frequency ≥5%) being hematological toxicities in both groups. Conclusions: The addition of adebrelimab to chemotherapy significantly improved OS with an acceptable safety profile, supporting this combination as a new first-line treatment option for ES-SCLC. Efficacy outcomes Adebrelimab+Chemo (n=230) Placebo+Chemo (n=232) Median OS (95% CI), mo 15.3 (13.2-17.5) 12.8 (11.3-13.7) HR (95% CI)*, 1-sided log-rank p 0.72 (0.58-0.90); p=0.0017 12-mo OS rate (95% CI), % 62.9 (56.3-68.8) 52.0 (45.4-58.2) 24-mo OS rate (95% CI), % 31.3 (24.9-37.9) 17.2 (12.1-23.0) Median PFS (95% CI), mo 5.8 (5.6-6.9) 5.6 (5.5-5.7) HR (95% CI)*, 1-sided log-rank p 0.67 (0.54-0.83); p <0.0001 6-mo PFS rate (95% CI), % 49.4 (42.4-56.0) 37.3 (30.7-43.9) 12-mo PFS rate (95% CI), % 19.7 (14.5-25.5) 5.9 (3.1-10.1) IRC-assessed ORR (95% CI), % 70.4 (64.1-76.3) 65.9 (59.5-72.0) Median DoR (95% CI), mo 5.6 (4.6-6.7) 4.6 (4.3-5.5) *Stratified Cox proportional-hazards model Citation Format: Ying Cheng, Jie Wang, Caicun Zhou, Wenxiu Yao, Qiming Wang, Xuhong Min, Gongyan Chen, Xingxiang Xu, Xingya Li, Fei Xu, Yong Fang, Runxiang Yang, Guohua Yu, Youling Gong, Jun Zhao, Yun Fan, Quan Liu, Lejie Cao, Yu Yao, Yunpeng Liu, Xiaoling Li, Jingxun Wu, Zhiyong He, Kaihua Lu, Liyan Jiang, Huiqing Yu, Chengping Hu, Wenhua Zhao, Jian Zhao, Gang Wu, Dingzhi Huang, Chengshui Chen, Cuimin Ding, Baihong Zhang, Xiuwen Wang, Hui Luo, Baolan Li, Ben Zhang, Haowen Li, Ke Ma. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage SCLC: A phase 3 trial [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr CT038.
Books on the topic "Wang luo ying xiao"
2
zhen, Zhao nai. Wang luo ying xiao. Bei jing: Zhong guo lao dong she hui bao zhang chu ban she, 2003.
Find full text
5
ling, Deng shao. Wang luo ying xiao xue. Guang zhou: Zhong shan ta xue chu ban she, 2009.
Find full text
6
gen, Li you. Wang luo ying xiao xue. Bei jing: Zhong guo cai zheng jing ji chu ban she, 2001.
Find full text
9
fei, Yan peng. Quan wang ying xiao: Yong hu zai na li,Ying xiao jiu gai chu xian zai nei li = Whole network marketing. Guang zhou: Guang dong ren min chu ban she, 2018.
Find full text
10
li, Zhou. Wang luo ying xiao shi wu. Bei jing: Bei jing shi fan ta xue chu ban she, 2011.
Find full textBook chapters on the topic "Wang luo ying xiao"
1
Taber, Douglass F. "Organocatalyzed C-C Ring Construction: The Thomson Synthesis of Streptorubin B." In Organic Synthesis. Oxford University Press, 2013. http://dx.doi.org/10.1093/oso/9780199965724.003.0072.
Full textAbstract:
Jinxing Ye of the East China University of Science and Technology used (Tetrahedron Lett. 2011, 52, 2715) the Hayashi catalyst to direct the addition of 2 to 1, to give the cyclopropane 3. Jia-Rong Chen and Wen-Jing Xiao of Central China Normal University employed (J. Org. Chem. 2011, 76, 281) a urea catalyst for the addition of 5 to 4. Yasumasa Hamada of Chiba University devised (Tetrahedron Lett. 2011, 52, 987) a different urea catalyst for the addition of 7 to 8, to control both the absolute and relative configuration of 9. Jiyong Hong of Duke University showed (Tetrahedron Lett. 2011, 52, 2468) that the imidazolium-mediated cyclization of 10 proceeded with high diastereoselectivity to give 11. Yixin Lu of the National University of Singapore optimized (J. Am. Chem. Soc. 2011, 133, 1726) a dipeptide-derived phosphine to catalyze the addition of 12 to 13. Karl A. Scheidt of Northwestern University combined (Angew. Chem. Int. Ed. 2011, 50, 1678) a triazolium catalyst with super-stoichiometric Ti(O- i Pr)4 to effect the addition of 15 to 4, to give 16. En route to malyngamide C, Xiao-Ping Cao of Lanzhou University condensed (J. Org. Chem. 2011, 76, 3946) the prochiral commercial monoketal 17 with nitrosobenzene, using proline as a catalyst, to prepare 18. Hong Wang of Miami University showed (Angew. Chem. Int. Ed. 2011, 50, 3484) that a lanthanide-complexed α-amino amide was effective for catalyzing the addition of the prochiral 19 to 4, to give 20. Alexandre Alexakis of the Université de Genève and John C. Stephens of the National University of Ireland, Maynooth, established (Angew. Chem. Int. Ed. 2011, 50, 5095) that the Hayashi catalyst was effective for mediating the addition of 22 to 21, to give the diene 23. Ying-Chun Chen of Sichuan University and Karl Anker Jørgensen of Aarhus University used (J. Am. Chem. Soc. 2011, 133, 5053) the same catalyst for the addition of 24 to 25. The Hayashi catalyst appeared again in the report (Chem. Comm. 2011, 47, 3828) by Magnus Reuping of RWTH Aachen University of the addition of 27 to 28.